

**Prof MARC ANSARI GROUP PUBLICATIONS  
CANSEARCH RESEARCH LABORATORY  
(since the creation of the laboratory 2011)**

**1. ORIGINAL PUBLICATIONS**

**2011**

1. Bieri S, Roosnek E, Ozsahin H, Huguet S, Ansari M, Trombetti A, Helg C, Chapuis B, Miralbell R, Passweg J, Chalandon Y  
*Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation*  
Eur J Haematol, vol. 87 (2011), No 2, pp. 138-147
2. Ansari M, Vukicevic M, Rougemont AL, Moll S, Parvex P, Gumy-Pause F, Chalandon Y, Passweg J, Ozsahin H, Roosnek E  
*Do NK cells contribute to the pathophysiology of transplant-associated thrombotic microangiopathy?*  
Am J Transplant, vol. 11 (2011), No 8, pp. 1748-1752
3. Brunsvig KL, Zenobi M, Rilliet B, El Hassani Y, de Haller R, Ansari M, Lobrinus JA, Hanquinet S, Fluss J  
*Primary leptomeningeal melanocytosis in a 10-year-old girl: a challenging diagnosis with a poor prognosis*  
J Child Neurol, vol. 26 (2011), No 11, pp. 1444-1448
4. Weber DC, Zilli T, H.P. HP, Nouet P, Gumy Pause F, Pica A  
*Intensity modulated radiation therapy or stereotactic fractionated radiotherapy for infratentorial ependymoma in children: a multicentric study*  
Journal of neuro-oncology. vol. 102 (2011), pp. 295-300
5. Ansari M, Gollut S, Stuckelberger S  
*Faut-il un suivi des familles après le décès d'un enfant en oncologie pédiatrique ?*  
Réseau francophone de soins palliatifs pédiatriques (09.2011)  
[http://www.pediatriepalliative.org/Edito-Archives\\_a21.html](http://www.pediatriepalliative.org/Edito-Archives_a21.html)

**2012**

6. Von der Weid NX, Ansari M  
*Hémo-oncologie pédiatrique: de la biologie cellulaire aux traitements ciblés et individualisés*  
Rev Med Suisse, vol. 8 (2012), No 329, pp. 403-408
7. Ansari M, Strunk D, Schallmoser K, Delco C, Rougemont AL, Moll S, Villard J, Gumy Pause F, Chalandon Y, Parvex P, Passweg J, Ozsahin H, Kindler V  
*Third-party mesenchymal stromal cell infusion is associated with a decrease in thrombotic microangiopathy symptoms observed posthematopoietic stem cell transplantation*  
Pediatr Transplant, vol. 16 (2012), No 2, pp. 131-136
8. Gumy Pause F, Pardo B, Koshbeen-Boudal M, Ansari M, Gayet-Ageron A, Sappino AP, Attiyeh EF, Ozsahin H  
*GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma*  
Genes Chromosomes Cancer, vol. 51 (2012), No 2, pp. 174-185

9. Ansari M, Rougemont AL, Le Deist F, Ozsahin H, Duval M, Champagne MA, Fournet JC  
*Secondary pulmonary alveolar proteinosis after unrelated cord blood hematopoietic cell transplantation*  
Pediatr Transplant, vol. 16 (2012), No 5, pp. E146-E149
10. Ansari M, Sauty G, Labuda M, Gagné V, Rousseau J, Moghrabi A, Laverdière C, Sinnett D, Krajcinovic M  
*Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia*  
Pharmacogenomics J, vol. 12 (2012), No 5, pp. 386-394
11. Ansari M, Uppugunduri CR, Déglon J, Théorêt Y, Versace F, Gumy Pause F, Ozsahin H, Dayer P, Desmeules J, Daali Y  
*A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography / tandem mass spectrometry*  
Rapid Commun Mass Spectrom, vol. 26 (2012), No 12, pp. 1437-1446
12. Versace F, Uppugunduri CR, Krajcinovic M, Théorêt Y, Gumy Pause F, Mangin P, Staub C, Ansari M  
*A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry*  
Anal Bioanal Chem, vol. 404 (2012), No 6-7, pp. 1831-1838
13. Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajcinovic M, Ansari M  
*Transcriptional regulation of CYP2C19 and its role in altered enzyme activity*  
Curr Drug Metab, vol. 13 (2012), No 8, pp. 1196-1204
14. Sappino AP, Buser R, Seguin Q, Fernet M, Lesne L, Gumy-Pause F, Reith W, Favaudon V, Mandriota SJ  
*The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage*  
Oncogenesis, vol. 1 (2012), e7
15. Sappino AP, Buser R, Lesne L, Gimelli S, Bena F, Belin D, Mandriota SJ  
*Aluminium chloride promotes anchorage-independent growth in human mammary epithelial cells*  
Journal of applied toxicology, vol. 32 (2012), pp. 233-243
16. Wunder D, Perey L, Ahtari C, Ambrosetti A, Bellavia M, Delaloye JF, de Ziegler D, Gumy-Pause F, Helg C, Ketterer N, Petignat P, Primi MP, Rosselet-Christ A, and Zaman K  
*Fertility preservation in cancer patients. Review of the French speaking part of Switzerland and recommendations for different situations*  
Swiss medical weekly, vol. 142 (2012), w13645
17. Uppugunduri CR, Ansari M  
*Influence of age, sex, and haplotypes of thiopurine methyltransferase (TPMT) gene on 6-mercaptopurine toxicity in children with acute lymphoblastic leukemia*  
Eur J Clin Pharmacol, vol. 68 (2012), No 5, pp. 887-888

## 2013

18. Labarinas S, Gumy Pause F, Rougemont AL, Schäppi MG, Barazzone-Argiroffo C, Bassweg J, Merlini L, Baerlocher GM, Oppliger Leibundgut E, Porret NA, Ozsahin H, Ansari M  
*Is acute fibrinous and organizing pneumonia the expression of immune dysregulation ?*  
J Pediatr Hematol Oncol, vol. 35 (2013), No 2, pp. 139-143
19. Ceschi C, Rauber-Lüthy C, Kupferschmidt H, Banner NR, Ansari M, Krähenbühl S, Taegtmeier AB  
*Acute calcineurin inhibitor overdose : analysis of cases reported to a national poison centre between 1995 and 2011*  
Am J Transplant, vol. 13 (2013), No 3, pp. 786-795
20. Korchi AM, Garibotto V, Ansari M, Merlini L  
*Pseudoprogression after proton beam irradiation for a choroid plexus carcinoma in pediatric patient: MRI and PET imaging patterns*  
Childs Nerv Syst, vol. 29 (2013), No 3, pp. 509-512

21. Ansari M, Rezgui MA, Théoret Y, Meziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Pryzbila C, Duval M, Champagne M, Peters C, Bittencourt H, Krajinovic M  
*Glutathione S transferase gene variations influence busulfan pharmacokinetics and outcome of haematopoietic stem cell transplantation in pediatric patients*  
Bone Marrow Transplant, vol. 48 (2013), No 7, pp. 939-946
22. Tyagi AK, Pradier A, Baumer O, Uppugunduri CR, Huezio-Diaz P, Posfay-Barbe KM, Roosnek E, Ansari M.  
*Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma.*  
Virology, vol. 10 (2013), No 191 (8 p.)
23. Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy Pause F, Chalandon Y, Tiercy JM, Schechter T, Gassas A, Doyle JD, Dupuis L, Duval M, Krajinovic M, Villard J  
*The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children*  
Plos One, vol. 8 (2013), No 8, p. e72141 (8 p.)
24. Hauri D, Spycher B, Huss A, Zimmermann F, Grotzer M, von der Weid N, Weber D, Spoerri A, Kuehni CE, Rösli M + Swiss national cohort + Swiss paediatric oncology group (SPOG) [including Ansari M]  
*Domestic radon exposure and risk of childhood cancer: a prospective census-based cohort study*  
Environ Health Perspect, vol. 121 (2013), No 10, pp. 1239-1244
25. Rueegg CS, Gianinazzi ME, Michel G, von der Weid NX, Bergstraesser E, Kuehni CE + Swiss paediatric oncology group (SPOG) [including Ansari M]  
*Do childhood cancer survivors with physical performance limitations reach healthy activity levels?*  
Pediatr Blood Cancer, vol. 60 (2013), No 10, pp. 1714-1720
26. Gollut S, Stückelberger S, Meier S, Mamie C, Humbert N, Ansari M  
*Le suivi des familles après le décès d'un enfant en onco-hématologie pédiatrique : un besoin?*  
Médecine Palliative, 2013 (accepted)
27. Ligue genevoise contre le cancer [including Ansari M]  
*L'enfant face au cancer : une sélection de livres, de vidéos et de sites web pour les 3-16 ans et leurs parents*  
Genève : Université / Faculté de médecine / Centre de documentation en santé, 2013. – 32 p.

## **2014**

28. Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H  
*Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation*  
Ther Drug Monit, vol. 36 (2014), No 1, pp. 93-99
29. Marek A, Stern M, Chalandon Y, Ansari M, Ozsahin H, Güngör T, Gerber B, Kühne T, Passweg JR, Gratwohl A, Tichelli A, Seger R, Schanz U, Halter J, Stussi G  
*The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT*  
Bone Marrow Transplant, vol. 49 (2014), No 1, pp. 55-61
30. Uppugunduri CS, Duval M, Bittencourt H, Krajinovic M, Ansari M  
*The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation*  
Pharmacogenomics J, vol. 14 (2014), No 3, pp. 263-271
31. Montaruli E, Wildhaber B, Ansari M, Birraux J  
*Adenovirus-induced obstructive uropathy with acute renal failure in an immunodeficiency child*  
Urology, vol. 83 (2014), No 01, pp. 217-219

32. Rock N, Mattiello V, Judas C, Huezo-Diaz P, Bourquin JP, GumyPause F, Ansari M  
*Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child*  
Pediatr Hematol Oncol, vol. 31 (2014), No 2, pp. 143-148
33. Gianinazzi ME, Essig S, Rueegg CS, von der Weid NX, Brazzola P, Kuehni CE, Michel G; Swiss Paediatric Oncology Group (SPOG) [including Ansari M]  
*Information provision and information needs in adult survivors of childhood cancer*  
Pediatr Blood Cancer, vol. 61 (2014), No 2, pp. 312-318
34. Hauri DD, Spycher B, Huss A, Zimmermann F, Grotzer M, von der Weid N, Spoerri A, Kuehni CE, Rösli M + Swiss national cohort + Swiss paediatric oncology group [including Ansari M]  
*Exposure to radio-frequency electromagnetic fields from broadcast transmitters and risk of childhood cancer: a census-based cohort study*  
Am J Epidemiol, vol. 179 (2014), No 7, pp. 843-851
35. Wengenroth L, Rueegg CS, Michel G, Essig S, Ammann RA, Bergstraesser E, Kuehni CE + Swiss paediatric oncology group (SPOG) [including Ansari M]  
*Life partnerships in childhood cancer survivors, their siblings, and the general population*  
Pediatr Blood Cancer, vol. 61 (2014), No 3, pp. 538-545
36. Gianinazzi ME, Rueegg CS, von der Weid NX, Niggli FK, Kuehni CE, Michel G + Swiss paediatric oncology group (SPOG) [including Ansari M]  
*Mental health-care utilization in survivors of childhood cancer and siblings: the Swiss childhood cancer survivor study*  
Support Care Cancer, vol. 22 (2014), No 2, pp. 339-349
37. Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajcinovic M, Ansari M  
*Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in children*  
Curr Drug Metab, vol. 15 (2014), No 3, pp. 251-264
38. Von Laer Tschudin L, Schwitzgebel VM, von Scheven-Gête A, Blouin JL, Hofer M, Hauschild M, Ansari M, Stoppa-Vaucher S, Phan-Hug F  
*Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy*  
Pediatr Diabetes [Epub ahead of print]
39. Beauverd Y, Roosnek E, Tirefort Y, Nagy-Hulliger M, Bernimoulin M, Tsopra O, Ansari M, Dantin C, Casini A, Grandjean AP, Chigrinova E, Masouridi-Levrat S, Chalandon Y  
*Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell-depletion*  
Biol Blood Marrow Transplant, vol 9 (2014), pp. 1322-1328
40. Tyagi AK, Huezo-Diaz P, Ansari M  
*Individualized treatment for children undergoing hematopoietic stem cell transplantation?*  
Per Med, vol 11 (2014), pp. 463-466
41. Tyagi AJ, Uppugunduri CR, Huezo-Diaz P, Krajcinovic M, Ansari M  
*Can pharmacogenetics and pharmacokinetics of busulfan be used to individualize treatment for children undergoing hematopoietic stem cell transplantation?*  
Bulletin suisse du cancer (in press)
42. J. R. Rischewski, Ansari M and all of the head SPOG station Pediatric Oncology in Switzerland  
*Infrastructure and Results*  
Bulletin suisse du cancer (in press)

## 2015

43. Arni D, Gumy-Pause, Ansari M, Mc Lin V.  
*Successful liver transplantation in a child with acute-on-chronic liver failure and acquired thrombotic thrombocytopenic liver transplantation*, vol 21 (2015), pp. 704-6
44. Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Gumy-Pause F, Ansari M.  
*Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism*. *Oncotarget*, vol 6(2015), pp. 18558-76
45. Imke bartelink et al,  
*Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study*.  
BBMT 2014 Biology of Blood and Marrow Transplantation (Impact Factor: 3.35). 02/2015; 21(2):S102-S103.  
DOI: 10.1016/j.bbmt.2014.11.124
46. Maja Krajcinovic, Jessica Elbared, Simon Drouin, Laurence Bertout, Aziz Rezgoui, Marc Ansari, Marie-Josée Raboisson, Steven Lipshultz, Lewis Silverman, Stephen Sallan, Donna Neuberg, Jeffery Kutok, Caroline Laverdière, Daniel Sinnott, and Gregor Andelfinger .  
*Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia*.  
The pharmacogenomic journal 2015, Sep 8. doi: 10.1038/tpj.2015.63. [Epub ahead of print]
47. Siest G, Auffray C, Taniguchi N, Ingelman-Sundberg M, Murray H, Visvikis-Siest S, Ansari M, Marc J, Jacobs P, Meyer U, Van Schaik RH, Müller MM, Wevers RA, Simmaco M, Kussmann M, Manolopoulos VG, Alizadeh BZ, Beastall G, Németh G.  
*Systems medicine, personalized health and therapy*.  
*Pharmacogenomics*, vol 16(2015), pp. 1527-3
48. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators dont Ansari M].  
*Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial*.  
*J Clin Oncol*. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1.
49. Martin Adam, Claudia Kuehni, Adrian Spoerri, Kurt Schmidlin, Fabienne Gumy-Pause, Pierluigi Brazzola, Nicole Probst-Hensch, Marcel Zwahlen for the Swiss Pediatric Oncology Group (SPOG) and the Swiss National Cohort Study Group (SNC)  
*Socioeconomic status and childhood leukemia incidence in Switzerland*  
*Front Oncol*. 2015 Jun 30;5:139

50. Emmanuel Levrat, Eddy Roosnek, Stavroula Masouridi, Bilal Mohty, Marc Ansari, Jean Villard, Jakob Robert Passweg and Yves Chalandon.  
*Very long term stability of mixed chimerism after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.*  
Bone Marrow Research, octobre 2015
51. Curtis P, Ansari M.  
*Influence of glutathione S-transferase gene polymorphism on busulfan pharmacokinetics and outcome of hematopoietic stem cell transplantation in thalassemia pediatric patients.*  
BMT, 2016;51(83):377-83
52. Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group ) [dont Ansari M].  
*Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial.*  
Lancet. 2015 Sep 19;386(9999):1156-64. doi: 10.1016/S0140-6736(14)62395-3. Epub 2015 Jul 9.
53. Carnesecci S, Rougemont AL, Doroshow JH, Nagy M, Mouche S, Gumy-Pause F, Szanto I. *The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large cell lymphoma cell lines.* Free Radic Biol Med. 2015 Jul;84:22-9.
54. Schindler M, Mitter V, Bergstraesser E, Gumy-Pause F, Michel G, Kuehni CE; Swiss Paediatric Oncology Group (SPOG).  
*Death certificate notifications in the Swiss Childhood Cancer Registry: assessing completeness and registration procedures.*  
Swiss Med Wkly. 2015 Dec 23;145

## 2016

55. Yan Beauverd, Eddy Roosnek, Yordanka Tirefort, Carole Dantin, Marc Ansari, Olga Tsopra, Stavroula Masouridi-Levrat, Yves Chalandon.  
*Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with non T-cell-depleted graft when stratified by the refined disease risk index.*  
BMT 2016
56. Wangmo, T. De Clercq, E., Ruhe, K., Beck-Popovic, M., Rischewski, J., Angst, R., Ansari, M., & Elger, B.S.  
*Better to Know than to Imagine: Including children in their healthcare.*  
AJOB Empirical Research, 2016
57. Matthias Schindler, MSc , Ben D. Spycher, PhD , Roland A. Ammann, MD , Marc Ansari, MD , Gisela Michel, PhD , Claudia E. Kuehni, MD, MSc , for the Swiss Paediatric Oncology Group (SPOG).  
*Cause Specific Long Term Mortality in Survivors of Childhood Cancer in Switzerland: A Population Based Study.*  
The International Journal of Cancer, février 2016
58. Chakradhara Rao Satyanarayana Uppugunduri, Marc Ansari.  
*A myriad aberrations on information of ontogeny of drug metabolizing enzymes in pediatric population : an obstacle for personalizing drug therapy in pediatric population.*  
Drug Metabolism Letters, février 2016

59. Luzius Mader, Corina S. Rueegg, Janine Vetsch, Johannes Rischewski, Marc Ansari, Claudia E. Kuehni, Gisela Michel, for the Swiss Paediatric Oncology Group (SPOG).  
*Employment Situation of Parents of Long-term Childhood Cancer Survivors.*  
Plos one 2016 march
60. Lupatsch JE, Wengenroth L, Rueegg CS, Teuffel O, Gumy-Pause F, Kuehni CE, Michel G; Swiss Paediatric Oncology Group.  
*Follow-up care of adolescent survivors of childhood cancer: The role of health beliefs.*  
Pediatr Blood Cancer. 2016 Feb;63(2):318-25.
61. Tenzin Wangmoa, Katharina M. Ruhea, Domnita O. Badaraua, Thomas Kühneb, Felix Nigglic, Bernice S. Elger+ Swiss paediatric oncology group (SPOG) [dont Ansari M].  
*Parents' and patients' experiences with paediatric oncology care in Switzerland - Satisfaction and some burdles*  
Swiss Medical Weekly, march 2016
62. Schluckebier, Dominique, McLin, Valérie A, Kanavaki, Ino, Ansari Marc, Wildhaber, Barbara E.  
*The role of liver transplantation in undifferentiated embryonal sarcoma of the liver in children.*  
Journal of Pediatric Hematology/Oncology, 2016
63. Zimmermann K, Bergstraesser E, Engberg S, Ramelet AS, Marfurt-Russenberger K, Von der Weid N, Grandjean C, Fahrni-Nater P, Cignacco E.  
*When parents face the death of their child: a nationwide cross-sectional survey of parental perspectives on their child's end-of life care.*  
PELICAN Consortium. [dont Ansari M], BMC Palliat Care. 2016 Mar 9;15:30. doi: 10.1186/s12904-016-0098-3.
64. Ruhe, K.M., Wangmo, T., de Clercq, E., Ansari, M., Kühne, T., Niggli, F., & Elger B.S., for the SPOG.  
*Putting patient participation into practice in pediatrics - Results from a qualitative study in pediatric oncology.*  
European Journal of Pediatrics. 2016
65. Patricia Huezo-Diaz, Chakradhara Rao Uppugunduri, Jayaraman Muthukumar, Mohamed Rezgui, Christina Peters, Peter Bader, Michel Duval, Henriette Bittencourt, Maja Krajinovic, Marc Ansari.  
*Association of CTH Variant with Sinusoidal Obstruction Syndrome in Children Receiving Intravenous Busulfan and Cyclophosphamide before Hematopoietic Stem Cell Transplantation.*  
The pharmacogenomic journal, july 2016
66. I.H. Bartelink, A. Lalmohamed , E.M.L. van Reij, C.C. Dvorak, R.M. Savic, J. Zwaveling, R.G.M. Bredius, A.C.G. Egberts, M. Bierings, M. Kletzel, P.J. Shaw, C.E. Nath, G. Hempel, M. Ansari, M. Krajinovic, Y. Theoret, M. Duval, R. Keizer, H. Bittencourt, M. Hassan, T. Gungor, R.F. Wynn, P. Veys, G.D.E. Cuvelier, S. Marktel, R. Chiesa, M.J. Cowan , M.A. Slatter, M. K. Stricherz, C. Jennissen , J.R. Long-Boyle, J.J. Boelens.  
*A New Harmonized Approach to Estimate Associate Busulfan Exposure Predicts with Survival and Toxicity after Hematopoietic Cell Transplantation in Children and Young Adults: a Multicenter Retrospective Cohort Analysis.*  
The Lancet Hematology, July 2016
67. Fabiën Belle , Laura Wengenroth, Annette Weiss, Grit Sommer, Maja Beck Popovic, Marc Ansari, Murielle Bochud, Claudia Kuehni for the Swiss Paediatric Oncology Group (SPOG).  
*Low adherence to dietary recommendations in adult childhood cancer survivors.*  
Clinical Nutrition, july 2016 (IF 4.487).
68. Vid Mlakar, Patricia Huezo-Diaz Curtis, Chakradhara Rao Uppugunduri Satyanarayana, Maja Krajinovic, Marc Ansari.  
*Pharmacogenomics in Pediatric Oncology: Review of Gene–Drug Associations for Clinical Use.*  
International journal of molecular science. 2016 Sep 8;17(9). pii: E1502.

69. Katharina M. Ruhe, Domnita O. Badarau, Pierluigi Brazzola, Heinz Hengartner, Bernice S. Elger, Tenzin Wangmo and for the Swiss Pediatric Oncology Group (SPOG) [dont Ansari M].  
*Participation in pediatric oncology : views of child and adolescent patients.*  
Psychooncology, vol 25(2016), pp. 1036-42.
70. Michel G, Gianinazzi ME, Eiser C, Bergstraesser E, Vetsch J, von der Weid NX, Kuehni CE and for the Swiss Pediatric Oncology Group (SPOG) [dont Ansari M].  
*Preferences for the organization of long-term follow-up in childhood cancer survivors. European Journal of Cancer Care.*  
DOI: 10.1111/ecc.12560
71. Adelina E. Acosta-Martin, Paola Antinori, Chakradhara Rao S. Uppugunduri, Youssef Daali, Marc Ansari, Alexander Scherl, Markus Müller, Pierre Lescuyer .  
*Detection of busulfan adducts on proteins.*  
Rapid Communications in Mass Spectrometry, 2016 Sep 6. doi: 10.1002/rcm.7730. [Epub ahead of print]
72. Vangelis G. Manolopoulos, Ron H.N. van Schaik, Sophie Visvikis-Siest, Janja Marc, Maurizio Simmaco, Peter Jacobs, Ingolf Cascorbi, Marc Ansari, Adrian Llerena.  
*In Memoriam Gérard Siest*  
Drug Metabol Pers Ther 2016
73. Laura Marquardt<sup>1</sup>, Marc Lacour<sup>2</sup>, Miriam Hoernes<sup>1</sup>, Lennart Opitz<sup>3</sup>, Rita Lecca<sup>3</sup>, Benjamin Volkmer<sup>1</sup>, Janine Reichenbach<sup>1</sup>, Daniel Hohl<sup>4</sup>, Marc Ansari<sup>5</sup>, Hulya Ozsahin<sup>5\*</sup>, Tayfun Güngör<sup>6</sup>, Jana Pachlopnik Schmid<sup>1</sup>.  
*Unusual dermatological presentation and immune phenotype in SCID due to an IL7R mutation : the value of whole exome sequencing and the potential benefit of newborn screening .*  
Journal of the European Academy of Dermatology & Venereology, july 2016.
74. Vid Mlakar, Patricia Huezo Diaz Curtis, Pierre Baumann, Roland P Bühlmann, Peter Meier-Abt, Urs A Meyer, Marc Ansari.  
*Creation of The Swiss group of Pharmacogenomics and Personalized Therapy (SPT),*  
Bulletin Suisse du Cancer, septembre 2016
75. Marc Ansari, Rudolf Maibach on behalf of the Kids Liver CANSEARCH Group .  
*Hepatoblastoma in Switzerland.*  
Bulletin suisse du cancer ,Krebsbulletin aout 2015
76. André O. von Bueren, Carmen Ares, Andrea Bartoli, Joel Fluss, Céline Girardin, Denis Migliorini, Laura Merlini, Doron Merkler, Marc Ansari.  
*Medulloblastoma in children and adults : One distinct disease entity ?*  
Bulletin du cancer Suisse, 2016
77. Friedrich C\*, von Bueren AO\*, Kolevatova L, Bernreuther C, Grob T, Sepulveda-Falla D, van den Boom L, Westphal M, Simon R, Glatzel M.  
*Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.*  
Childs Nerv Syst. Vol 32 (2016), pp. 281-90.
78. Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, von Bueren AO, Krauss J, Schweitzer T, Vince GH, Picard D, Eyrich M, Rosenwald A, Ramaswamy V, Taylor MD, Remke M, Monoranu CM, Beilhack A, Schlegel PG, Wölfl M. *MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties.* BMC Cancer, Vol 17(2016), pp.115.



79. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S, Chotewutmontri S, Bewerunge-Hudler M, Schick M, Schlesner M, Hutter B, Taylor L, Borst T, Sutter C, Bartram CR, Milde T, Pfaff E, Kulozik AE, von Stackelberg A, Meisel R, Borkhardt A, Reinhardt D, Klusmann JH, Fleischhack G, Tippelt S, Dirksen U, Jürgens H, Kramm CM, von Bueren AO, Westermann F, Fischer M, Burkhardt B, Wöbmann W, Nathrath M, Bielack SS, Frühwald MC, Fulda S, Klingebiel T, Koscielniak E, Schwab M, Tremmel R, Driever PH, Schulte JH, Brors B, von Deimling A, Lichter P, Eggert A, Capper D, Pfister SM, Jones DT, Witt O.  
*Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.*  
Eur J Cancer, vol 65(2016), pp.91-101
80. Von Bueren AO, Seidel C, Friedrich C.  
*Comment on: Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?*  
J Neurooncol. Vol 129(2016), pp.189-91.
81. Uppugunduri CR, George M.  
*Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition-The Dream of Translational Medicine.*  
J Cardiovasc Pharmacol, vol 67(2016), pp. 191-2.
82. Bosilkovska M, Ing Lorenzini K, Uppugunduri CR, Desmeules J, Daali Y, Escher M.  
*Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.*  
Clin Ther, vol 38(2016), pp.216-20.
83. Patricia Huezo Diaz Curtis, Uppugunduri CR, Marc Ansari.  
*Potential Predictive Biomarkers used to optimize treatments for Sinusoidal Obstruction Syndrome in pediatric Hematopoietic stem cell transplantation,*  
Bulletin Suisse du Cancer, October 2016 (in press)

## 2017

84. Bresters D, Lawitschka A, Cugno C, Pötschger U, Dalissier A, Michel G, Vettenranta K, Sundin M, Al-Seraihy A, Faraci M, Sedlacek P, Versluys AB, Jenkins A, Lutz P, Gibson B, Leiper A, Diaz MA, Shaw PJ, Skinner R, O'Brien TA, Salooja N, Bader P, Peters C. On behalf of the Pediatric Working disease of EBMT [dont Ansari M].  
*Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years : TBI is what really matters.*  
Bone Marrow Transplant, vol. 51 (2016), No 11, pp. 1482-1489
85. Schindler M, Belle FN, Grotzer MA, von der Weid NX, Kuehni CE; Swiss Paediatric Oncology Group (SPOG) [dont Ansari M].  
*Childhood cancer survival in Switzerland (1976-2013) : Time-trends and predictors.*  
Int J Cancer, vol. 140 (2017), No 1, pp. 62-74
86. Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P.  
*Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration.*  
Lancet Oncol, 2016 Nov

87. J-H Dalle, G Lucchini, A Balduzzi, M Ifversen, K Jahnukainen, K T Macklon, A Ahler, A Jarisch, M Ansari, E Beohou, D Bresters, S Corbacioglu, A Dalissier, C Diaz de Heredia Rubio, T Diesch, B Gibson, T Klingebiel, A Lankester, A Lawitschka, R Moffat, C Peters, C Poirot, N Saenger, P Sedlacek, E Trigos, K Vettenranta, J Wachowiak, A Willasch, M von Wolff, I Yaniv, A Yesilipek and P Bader.  
*State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29–30 September 2015.*  
BMT, 2017
88. Rost, M., Wangmo, T., Niggli, F., Hartmann, K., Hengartner, H., Ansari, M, Brazzola, P, Rischewski, J., Beck-Popovic, M., Kühne, T., Elger, B.S.  
*Parents' and physicians' perceptions of children's participation in decision making in pediatric oncology: A quantitative study.*  
Journal of Bioethical Inquiry, 2017
89. Visvikis-Siest S, Aldasoro Arguinano AA, Stathopoulou M, Xie T, Petrelis A, Weryha G, Froguel P, Meier-Abt P, Meyer UA, Mlakar V, Ansari M, Papassotiropoulos A, Dedoussis G, Pan B, Bühlmann RP, Noyer-Weidner M, Dietrich PY, Van Schaik R, Innocenti F, März W, Bekris LM, Deloukas P.  
*8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016.*  
Drug Metab Pers Ther. 2017 May 5.
90. M. H. Elayadi, M. Ansari, D. Sturm, G. H. Gielen, Monika Warmuth-Metz, C. M. Kramm, A.O. von Bueren.  
*High-Grade Glioma in Very Young Children: A Rare and Under-Investigated Patient Population.*  
Oncotarget, mai 2017
91. Selim Corbacioglu, Enric Carreras, Marc Ansari, Adriana Balduzzi, Simone Cesaro, Jean Hugues Dalle, Fiona Dignan, Brenda Gibson, Tayfun Güngör, Bernd Gruhn, Arjan Lankester, Franco Locatelli, Tony Pagliuca, Christina Peters, Paul Richardson, Ansgar Schulz, Petr Sedlacek, Jerry Stein, Karl-Walter Sykora, Jacek Toporski, Eugenia Trigos, Kim Vettenranta, Jacek Wachowiak, Elisabeth Wallhult, Robert Wynn, Isaac Yaniv, Akif Yesilipek, Mohamad Mohty, and Peter Bader.  
*Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation (EBMT).*  
BMT, june 2017
92. Adriana Balduzzi, Jean-Hugues Dalle, Kirsi Jahnukainen, Michael von Wolff, Giovanna Lucchini, Marianne Ifversen, Kirsten Tryde Macklon, Catherine Poirot, Tamara Diesch, Andrea Jarisch, Dorine Bresters, Isaac Yaniv, Brenda Gibson, Andre Willasch, Rubens Fadini, Luisa Ferrari, Anita Lawitschka, Astrid Ahler, Nicole Sängler, Selim Corbacioglu, Marc Ansari, Rebecca Moffat, Arnaud Dalissier, Eric Beohou, Petr Sedlacek, Arjan Lankester, Cristina Díaz de Heredia, Kim Vettenranta, Jacek Wachowiak, Akif Yesilipek, Eugenia Arjona, Thomas Klingebiel, Christina Peters, and Peter Bader  
*Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the Consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group.*  
BMT, june 2017
93. Federico Simonetta, Stavroula Masouridi-Levrat, Yan Beauverd, Olga Tsopra, Yordanka Tirefort, Caroline Stephan, Karolina Polchlopek, Amandine Pradier, Carole Dantin, Marc Ansari, Eddy Roosnek, Yves Chalandon.  
*Partial T-Cell Depletion Improves the Composite Endpoint Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation.*  
Leukemia and Lymphoma june 2017.

94. M Simonin, A Dalissier, M Labopin, A Willasch, M Zecca, A Mouhab, A Chybicka, A Balduzzi, L Volin, C Peters, P Bader, J-H Dalle on behalf of PDWP-EBMT [dont Ansari M].  
*More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Working Party*  
BMT apr 2017
95. Pierre Baumann, Roland P. Bühlmann, Alexander Jetter, Hugo Kupferschmidt, Peter Meier-Abt, Urs A. Meyer, Marc Ansari  
*Création du Groupe Suisse de Pharmacogénomique et de Thérapie Personnalisée (SPT).*  
Pipette-Swiss laboratory Medecine, Nr 3, juin 2016
96. Vid Mlakar, Simona Jurkovic Mlakar, Gonzalo Lopez Garcia, John Maris, Marc Ansari, Fabienne Gumy Pause.  
*11q deletion in neuroblastoma: a review of biological and clinical implications.*  
Molecular Cancer, July 2017, 16:114 (in press)
97. Chakradhara Rao S. Uppugunduri, Flavia Storelli, Vid Mlakar, Patricia Huezo-Diaz, Curtis Aziz Rezgui, Yves Théorêt, Denis Marino, Fabienne Doffey Lazeyras, Yves Chalandon, Peter Bader, Youssef Daali, Henriette Bittencourt, Maja Krajinovic, Marc Ansari.  
*The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Haematopoietic Stem Cell Transplantation.*  
Frontiers in Pharmacology, July 2017.
98. T Nava MA Rezgui, CRS Uppugunduri, P Huezo-Diaz Curtis, Y Théoret, M Duval, LE Daudt, M Ansari\*, M Krajinovic\*, H Bittencourt\*.  
*GSTA1 genetic variants and conditioning regimen: missing key factors in dosing guidelines of Busulfan in pediatric hematopoietic stem cell transplantation.*  
BBMT August 2017.
99. M Ansari, P Huezo-Diaz Curtis, CRS Uppugunduri, MA Rezgui, T Nava, V Mlakar, L Lesne, Y Théoret, Y Chalandon, LL Dupuis, T Schechter, IH Bartelink, JJ Boelens, R Bredius, JH Dalle, S Azarnoush, P Sedlacek, V Lewis, M Champagne, C Peters, H Bittencourt and M Krajinovic. On Behalf of the Paediatric Disease Working Party of the European Society for Blood and Marrow Transplantation. *GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a Multicenter Study.* Oncotarget (in submission process)
100. Hutter G, Sailer M, Azad TD, von Bueren AO, Nollau P, Frank S, Tostado C, Sarvepalli D, Ghosh A, Ritz MF, Boulay JL, Mariani L. *Reverse phase protein arrays enable glioblastoma molecular subtyping.* Journal of Neurooncology. 2017 Apr;132(2):255-266.
102. Van Zanten SE, Baugh J, Chaney B, De Jongh D, Aliaga ES, Barkhof, Noltes J, De Wolf R, Van Dijk J, Cannarozzo A, Damen-Korbijn CM, Lieverst JA, Colditz N, Hoffmann M, Warmuth-Metz M, Bison B, Jones DT, Sturm D, Gielen GH, Jones C, Hulleman E, Calmon R, Castel D, Varlet P, Giraud G, Slavic I, Van Gool S, Jacobs S, Jadrijevic-Cvrlje F, Sumerauer D, Nysom K, Pentikainen V, Kivivuori SM, Leblond P, Entz-Werle N, von Bueren AO, Kattamis A, Hargrave DR, Hauser P, Garami M, Thorarinsdottir HK, Pears J, Gandola L, Rutkauskiene G, Janssens GO, Torsvik IK, Perek-Polnik M, Gil-da-Costa MJ, Zheludkova O, Shats L, Deak L, Kitanovski L, Cruz O, La Madrid AM, Holm S, Gerber N, Kebudi R, Grundy R, Lopez-Aguilar E, Zapata-Tarres M, Emmerik J, Hayden T, Bailey S, Biassoni V, Massimino M, Grill J, Vandertop WP, Kaspers GJ, Fouladi M, Kramm CM, van Vuurden DG; members of the SIOPE DIPG Network. *Development of the SIOPE DIPG network,*

registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. *Journal of Neurooncology*. 2017 Apr;132(2):255-266.

103. Janssens GO, Gandola L, Bolle S, Mandeville H, Ramos-Albiac M, van Beek K, Benghiat H, Hoeben B, Morales La Madrid A, Kortmann RD, Hargrave D, Menten J, Pecori E, Biassoni V, von Bueren AO, van Vuurden DG, Massimino M, Sturm D, Peters M, Kramm CM. *Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group*. *European Journal of Cancer*. 2017 Mar;73:38-47
104. Karremann M, Krämer N, Hoffmann M, Wiese M, Beilken A, Corbacioglu S, Dilloo D, Driever PH, Scheurlen W, Kulozik A, Gielen GH, von Bueren AO, Dürken M, Kramm CM *Haematological malignancies following temozolomide treatment for paediatric high-grade glioma*. *Eur J Cancer*. 2017 Jun 3;81:1-8. doi: 10.1016/j.ejca.2017.04.023.
- 105 Ripperger T, Bielack S, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, Debatin KM, Deubzer H, Dirksen U, Eckert C, Eggert A, Erlacher M, Fleischhack G, Frühwald MC, Gnekow A, Goehring G, Graf N, Hanenberg H, Hauer J, Hero B, Hettmer S, von Hoff K, Horstmann M, Hoyer J, Illig T, Kaatsch P, Kappler R, Kerl K, Klingebiel T, Kontny U, Kordes U, Körholz D, Koscielniak E, Kramm CM, Kuhlén M, Kulozik AE, Lamottke B, Leuschner I, Lohmann DR, Meinhardt A, Metzler M, Meyer LH, Moser O, Nathrath M, Niemeyer CM, Nustede R, Pajtler KW, Paret C, Rasche M, Reinhardt D, Rieß O, Russo A, Rutkowski S, Schlegelberger B, Schneider D, Schneppenheim R, Schrappe M, Schroeder C, von Schweinitz D, Simon T, Sparber-Sauer M, Spix C, Stanulla M, Steinemann D, Strahm B, Temming P, Thomay K, von Bueren AO, Vorwerk P, Witt O, Wlodarski M, Wössmann W, Zenker M, Zimmermann S, Pfister SM, Kratz CP. *Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology*. *Am J Med Genet A*. 2017 Apr;173(4):1017-1037. Review
107. Sunitha Kodidela, S Suresh Kumar, Chakradhara Rao Satyanarayana Uppugunduri. *Developmental pattern of hepatic drug-metabolizing enzymes in pediatric population and its role in optimal drug treatment*. *Arch Med Health Sci* 2017;5:115-22.
108. Choong E, CRS Uppugunduri, Marino D, Kuntzinger, M, Lazeyras FD, Lo Piccolo R, Chalandon Y, Peters C, Daali Y, Ansari M. *Therapeutic drug monitoring of busulfan for the health care management in pediatric patients: Focus on methods' cross-validation and long-term performance*. *Therapeutic Drug Monitoring* (submitted, in review)

### 3. ABSTRACTS PRESENTED TO INTERNATIONAL MEETINGS

#### 2011

1. Rigatou E, Gumy Pause F, Chalandon Y, Ansari M, Ozsahin AH  
*Post-transplant immune reconstitution after allogeneic stem cell transplantation in paediatric patients with high-risk leukaemia*  
European group for bone and marrow transplantation, 37th Annual meeting. Paris, avril 2011  
*Bone Marrow Transplant*, vol. 46 (2011), Suppl. No 1, pp. S149-S150
2. Marek A, Stern M, Chalandon Y, Ansari M, Güngör T, Passweg J, Gratwohl A, Seger R, Schanz U, Halter J, Stüssi G  
*Comparison of T-cell depletion in haplo-identical haematopoietic stem cell transplantation*  
European group for bone and marrow transplantation, 37th Annual meeting. Paris, April 2011  
*Bone Marrow Transplant*, vol. 46 (2011), Suppl. No 1, pp. S334-335
3. Gumy Pause F, Pardo B, Kohshbeen-Boudal M, Ansari M, Attiyeh EF, Ozsahin AH  
*Association of GSTP1 hypermethylation with reduced protein expression and its correlation with clinical stage in neuroblastoma*  
American society of clinical oncology, 47th Annual meeting. Chicago, June 2011  
*J Clin Oncol*, vol. 29 (2011), No 15S/II, No 9537
4. Rezgui MA, Ansari M, Thérot Y, Duval M, Vachon MF, Bittencourt H, Krajinovic M

*Genetic determinants of the busulfan pharmacokinetics*

12th International congress of human genetics. Montréal, October 2011

Abstract book, No 1418F

5. Bittencourt H, Ansari M, Théoret X, Champagne M, Duval M, Krajinovic M  
*Myeloblastic conditioning with pharmacokinetic-targeted intravenous busulfan and cyclophosphamide in unrelated cord blood transplantation for myeloid malignancies in children*  
American society of hematology, 53rd Annual meeting. San Diego, December 2011  
Blood, vol. 118 (2011), No 21, No 1965

**2012**

6. Ansari M, Théoret Y, Rezgui M, Mezziani S, Desjean C, Vachon M, Labuda M, Champagne M, Duval M, Peters C, Krajinovic M, Bittencourt H  
*Association between busulfan exposure and outcome in children receiving intravenous busulfan before haematopoietic stem cell transplantation*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, pp. S41-S42
7. Krajinovic M, Rezgui M, Théoret Y, Duval M, Mezziani S, Rousseau J, Labuda M, Pryzbilla C, Vachon M, Desjean C, Champagne M, Peters C, Bittencourt H, Ansari M  
*Glutathion S transferase gene variations influence busulfan pharmacokinetics and outcome of haematopoietic stem cell transplantation*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S41
8. Tirefort Y, Roosnek E, Paiano S, Levrat E, Casani A, Mothy B, Bernimoulin M, Nagy-Hulliger M, Grandjean A, Metthes T, Chigrinova E, Kami K, Ansari M, Kindler V, Ozsahin H, Masouridi S, Chalandon Y  
*Prognostic significance of EBMT risk score for the outcome of allogeneic haematopoietic stem cell transplantation after T-cell depletion*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S312
9. Nagy M, Ozsahin H, Ansari M, Preynat-Seauve O, Cerdan-Bruyère P, Chalandon Y, Rigal E  
*Effect of dysimmunity on blood group determination after allogeneic stem cell transplantation : a difficult case*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, pp. S341-S342
10. Chigrinova E, Roosnek E, Mothy B, Grandjean AP, Casani A, Ansari M, Ozsahin H, Nagy M, Tirefort Y, Levrat E, Bernimoulin M, Masouridi S, Chalandon Y  
*Allogeneic haematopoietic stem cell transplantation for non-Hodgkin lymphoma : a single-center experience*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, pp. S437-S439
11. Uppugunduri C, Théoret Y, Déglon J, Versache F, Gumy Pause F, Ozsahin H, Dayer P, Desmeules J, Daali Y, Ansari M  
*A simplified method for busulfan therapeutic drug monitoring using dried blood spot sampling in paediatric patients undergoing stem cell transplantation*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S38
12. Ansari M, Uppugunduri C, Bittencourt H, Gumy Pause F, Ferrari-Lacraz S, Chalandon Y, Ozsahin H, Tiercy JM, Duval M, Krajinovic M, Villard J  
*Anti HLA antibodies and outcome in pediatric cord blood transplantation*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S42
13. Rigatou E, Gumy Pause F, Mattiello V, Chalandon Y, Ansari M, Ozsahin H  
*Update on post transplant immune reconstitution after allogeneic stem cell transplantation in paediatric high risk leukaemia patients*

- European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, pp. S366-S367
14. Rigatou E, Gumy Pause F, Mattiello V, Chalandon Y, Ansari M, Ozsahin H  
*Diamond Blackfan anemia : when to transplant?*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S368
  15. Uppugunduri C, Versace F, Krajinovic M, Théoret Y, Gumy Pause F, Ozsahin H, Mangin P, Staub C, Ansari M  
*Quantification of sulfolane, a metabolite of busulfan in plasma by gas chromatography and tandem mass spectrometry: a new method for evaluating the role of sulfolane and metabolic fate of busulfan*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S381
  16. Repond B, Cristiano G, Ozsahin H, Gumy Pause F, Ansari M, Bernard V  
*Diet in the onco-hematology pediatric unit of the Geneva university hospital*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S460
  17. Flores P, Vuilloud C, Cristiano G, Ozsahin H, Gumy Pause F, Ansari M, Bernard V  
*Schooling of ill children – school social link : experience in a transplant unit*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S483
  18. Bernard V, Bouchardy M, Cristiano G, Ozsahin H, Gumy Pause F, Ansari M  
*Transdisciplinary project : enhancement of physical activity for long-term hospitalised onco-hematological children*  
European group for blood and marrow transplantation, 38th Annual meeting. Geneva, April 2012  
Bone Marrow Transplant, vol. 47 (2012), Suppl. No 1, p. S501
  19. Uppugunduri C, Gumy Pause F, Rezgui MA, Vachon MF, Desjean C, Labuda M, Duval M, Bittencourt H, Krajinovic M, Ansari M  
*Role of cytochrome P450 in the metabolic fate of busulfan as explored in pediatric patients undergoing hematopoietic stem cell transplantation*  
International society of paediatric oncology, 44th Congress. Londres, October 2012  
Pediatr Blood Cancer, vol. 59 (2012), No 6, p. 1094
  20. Huezo-Diaz P, Uppugunduri CS, Tyagi A, Krajinovic M, Ansari M  
*Association study between CTH gene variant and veno-occlusive disease in children receiving intravenous busulfan before hematopoietic stem cell transplantation*  
American society of hematology, 54th Annual meeting. Atlanta, December 2012  
Blood, vol. 120 (2012), Suppl. No 21, No 3025
  21. Bittencourt H, Théoret Y, Duval M, Krajinovic M, Ansari M  
*Pharmacokinetic and pharmacogenomics of busulfan in children undergoing cord blood transplantation*  
American society of hematology, 54th Annual meeting. Atlanta, December 2012  
Blood, vol. 120 (2012), Suppl. No 4143
  22. Mandriota S, Buser R, Seguin Q, Fernet M, Lesne L, Ozsahin H, Ansari M, Reith W, Favaudon V, Gumy-Pause F  
*Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in the DNA damage response of human neuroblastoma cells*  
Advances in Neuroblastoma Research, Toronto, June 2012
  23. Mandriota S, Buser R, Lesne L, Ozsahin H, Ansari M, Gumy-Pause F  
*Contribution of Ataxia Telangiectasia Mutated (ATM) loss of function to neuroblastoma progression*  
Advances in Neuroblastoma Research, Toronto, June 2012

## 2013

24. Patricia Huezo-Diaz, Chakradhara Uppugunduri, Anuj Tyagi, Mohamed Rezgui, Fanette Bernard, Yves Chalandon, Michel Duval, Henriette Bittencourt, Maja Krajcinovic, Marc Ansari.  
*Metabolic enzyme gene variants predispose children receiving a busulfan/cyclophosphamide-based myeloablative conditioning to venoocclusive disease.*  
39th Annual meeting. London, April 2013, Bone Marrow Transplantation, 48(2), 2013
25. Y.Beauverd, E.Roosnek, Y.Tirefort, M.Nagy-Hulliger, M.Bernimoulin, O.Tsopra, V.kindler, M.Ansari, C.Dantin, A.Casini, A-P. Granjean, E.Chigrinova, S.Masouridi-Levrat, Y.Chalandon.  
*Is there a difference in the disease risk index for outcome of patients undergoing allogenic haematopoietic stem cell transplantation after T-cell depletion?*  
39th Annual meeting. London, April 2013, Bone Marrow Transplant, P810, Bone Marrow Transplantation, v48(2), 2013
26. Mandriota SJ, Buser R, Lesne L, Ansari M, Gumy-Pause F, Belin D, Sappino AP.  
*Aluminium chloride transforms cultured mammary epithelial cells*  
Tenth Keele meeting on aluminium, Keele (UK), February 2013
27. Ansari M, Uppugunduri CRS, Rezgui MA, Théoret Y, Mezziani S, Vachon MF, Desjean C, Rousseau J, Labuda M, Przybyla C, Duval M, Champagne MA, Peters C, Bittencourt H, Krajcinovic M  
*Association of glutathione S-transferase gene variations, busulfan exposure and clinical outcomes in children receiving intravenous busulfan before hematopoietic stem cell transplantation.*  
Second ESPT Conference "Pharmacogenomics: From Cell to Clinic" Drug Metabolism and Drug Interactions, 28.3 (2013): A1-A48. Lisbon, September 2013.
28. Uppugunduri CRS, Daali Y, Rezgui MA, Huezo-Diaz P, Tyagi AK, Rousseau J, Duval M, Bittencourt H, Krajcinovic M, Ansari M.  
*Sulfolane levels and its relation to CYP2C9 genotypes in children receiving intravenous busulfan prior to hematopoietic stem cell transplantation.*  
Second ESPT Conference "Pharmacogenomics: From Cell to Clinic" Drug Metabolism and Drug Interactions, 28.3 (2013): A1-A48. Lisbon, September 2013.
29. Uppugunduri CRS, Daali Y, Rezgui MA, Huezo Diaz P, Tyagi AK, Rousseau J, Duval M, Bittencourt H, Krajcinovic M, Ansari M.  
*CYP2C9 genotypes associated with higher sulfolane levels in children receiving intravenous busulfan prior to hematopoietic stem cell transplantation.*  
Clinical therapeutics 2013; 35: e52-e53. EACPT 2013, Geneva, August 2013.
30. Uppugunduri CRS, Ansari M, Théorêt Y, Déglon J, Versace F, Gumy-Pause F, Dayer P, Desmeules J, Daali Y.  
*A Simplified Method For Busulfan Therapeutic Drug Monitoring Using Dried Blood Spot Sampling In Pediatric Patient Undergoing Stem Cell Transplantation.*  
Clinical therapeutics 2013; 35: e52-e53. EACPT 2013, Geneva, August 2013.
31. Uppugunduri CRS, Rezgui MA, Théoret Y, Huezo Diaz P, Tyagi AK, Mezziani S, Vachon MF, Desjean C, Duval M, Bittencourt H, Krajcinovic M, Ansari M.  
*Sulfolane (a metabolite of busulfan) levels could predict early occurrence of hemorrhagic cystitis in children receiving busulfan based myeloablative conditioning before hematopoietic stem cell transplantation.*  
American Society of Hematology, 55<sup>th</sup> Annual Meeting, New Orleans, December 2013  
Blood, vol. 122 (2013), No 21, No 4574
32. M Ansari, M A Rezgui, P Curtis, C R S Uppugunduri, M Duval, H Bittencourt, B Cappelli and M Krajcinovic.  
*Influence of GST gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem cell transplantation in Thalassemia pediatric patients.*  
American Society of Hematology, 55<sup>th</sup> Annual Meeting, New Orleans, December 2013

**2014**

33. Beauverd Y, Roosnek E, Tirefort Y, Ansari M, Dantin C, Tsopra O, Massouridi-Levrat S, Chalandon Y.  
*Validation of the revised disease risk index for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) after partial T-cell depletion*  
European group for bone and marrow transplantation, 40th Annual meeting. Milan, March 2014  
Bone Marrow Transplant, vol. 49 (2014), Suppl. No 1S, p. S154
34. Rod Fleury T, De Coulon G, Dhouib Chargui A, Ansari M, Lascombes P.  
*Isolated cervical Langerhans cell histiocytosis with neurological deficit and potential cervical spine instability : recuperation without surgical intervention*  
European musculo-skeletal oncology society, 27th Annual meeting. Vienna, Mai 2014
35. Mandriota S, Lesne L, Marino D, Ansari M, Gumy Pause F.  
*Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism*  
Advances in neuroblastoma research association, Annual meeting. Cologne, Mai 2014
36. M Ansari, C Uppugnduri, P Curtis, H Bittencourt, M Duval, M Krajcinovic.  
*Association Of Hemorrhagic Cystitis With GSTM1 And CYP2C9 Genotypes In Pediatric Patients Receiving Busulfan Based Conditioning Regimen Prior To Hematopoietic Stem Cell Transplantation.*  
Pediatric Blood & Cancer, 2014, 61(S2), S105-S433. 46th congress of the international society of paediatric oncology (SIOP) 2014. 22-25Th October , Toronto, Canada.
37. M Ansari, C Uppugnduri, P Curtis, H Bittencourt, M Duval, M Krajcinovic.  
*GSTA1 Haplotypes Influence Clearance Of Intravenous Busulfan And Occurrence Of Sinusoidal Obstructive Syndrome In Children Undergoing Hsct On Behalf Of The PDWP Of The EBMTgroup.*  
Pediatric Blood & Cancer, 2014, 61(S2), S105-S433. 46th congress of the international society of paediatric oncology (SIOP) 2014. 22-25Th October , Toronto, Canada.
38. Schindler M, Rueegg CS, Spycher BD, Ansari M, Ammann RA, Michel G, Kuehni CE for the Swiss Pediatric Oncology Group (SPOG).  
*Time-trends and predictors of childhood cancer survival in Switzerland*  
The European Symposium on Late Complications After Childhood Cancer 2014, Scotland
39. Schindler M, Spycher BD, Ammann RA,, Ansari M, Michel G, Kuehni CE.  
*Cause Specific Late Mortality Among Survivors of Childhood Cancer in Switzerland*  
The European Symposium on Late Complications After Childhood Cancer 2014, Scotland
40. Marc Ansari, Henrike Bittencourt, Michel Duval, Christina Peters, Maja Krajcinovic.  
*Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group.*  
ASH 2014 Publication Number: 424

**2015**

41. Arni D, Gumy-Pause, Ansari M, Mc Lin V.  
*Successful liver transplantation in a child with acute-on-chronic liver failure and acquired thrombotic thrombocytopenic.*  
IPTA congress 2015 held March 28-31, in San Francisco!delphine



42. A Greanjean, M Ansari, Y Chalandon.  
*Impact of T cell depletion techniques on post transplantation graft versus host disease after allogeneic HSCT with myeloablative conditioning.*  
P266, EBMT, Turquie, 2015
43. F Bernard, Crosazzo L<sup>2</sup>, Girardin C<sup>3</sup>, Yaron M<sup>4</sup>, Andrieu-Vidal I<sup>5</sup>, Phan-Hug F<sup>6</sup>, Wunder D<sup>7</sup>, Primi M.P<sup>7</sup>, Simon J.P<sup>8</sup>, Schwitzgebel V<sup>3</sup>, Streuli I<sup>4</sup>, Ansari M<sup>1</sup>, Beck-Popovic M<sup>2</sup>, Gumy-Pause F<sup>1</sup>.  
*Fertility preservation in female pediatric HSCT patient : A multidisciplinary approach for the french speaking part of switzerland.*  
P093, EBMT, Turquie, 2015
44. Olivier Schussler, José-Maria Rincon-Garriz, Priscilla Soulie, Marc Ansari, Marie-Luce Piallat, Vincent Kindler.  
*Collagen foam membranes colonized by human mesenchymal stromal cells efficiently inhibit allogeneic T lymphocyte proliferation in vivo.*  
P400, EBMT, Turquie, 2015
45. Schindler M, Rueegg CS, Spycher BD, Ansari M, Ammann RA, Michel G, Kuehni CE for the Swiss Pediatric Oncology Group (SPOG).  
*Cause-specific Late Mortality Among Survivors Of Childhood Cancer in Switzerland: a Population Based Cohort Study.* The Cancer Outcomes Conference 2015, 8-10 June 2015, Belfast
46. Arni D, Gumy-Pause F, Ansari M, Kremer Hovinga JA, McLin V.  
*Successful liver transplantation in a child with acute-on-chronic liver failure and acquired thrombotic thrombocytopenic purpura.*  
IPTA 2015
47. Mader Luzius, Michel Gisela, Vetsch Janine, Johannes Rischeweski, Marc Ansari, Claudia Kuehni.  
*Employment status and household income in parents of childhood cancer survivors*  
14<sup>th</sup> International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer  
June 11-13, 2015.
48. Patricia Huezo-Diaz, Chakradhara Rao Uppugunduri, Mohamed Aziz Rezgui, Chrisna Peters, Peter Bader, Michel Duval, Henrike Bittencourt, Maja Krajinovic and Marc Ansari.  
*Association of CTH Variant with Sinusoidal Obstruction Syndrome in Children Receiving Intravenous Busulfan and Cyclophosphamide before Hematopoietic Stem Stem.*  
ESPT, october Budapest 2015
49. Marc Ansari  
*Individualised therapy in Hematopoietic stem Cell transplantation.*  
ESPT, october Budapest 2015
50. Nava T, Ansari M, Theoret Y, Rezgui MA, Duval M, Bittencourt H, Krajinovic M.  
*GSTA1\*B1a haplotype influencing Busulfan clearance and dosing in conditioning before HSCT.*  
ASH décembre 2015
51. Nava T, Ansari M, Theoret Y, Rezgui MA, Duval M, Krajinovic M, Bittencourt H.  
*GSTA1 genotype influencing performance of initial Bu prediction methods during conditioning before HSCT.*  
ASH décembre 2015
52. Simonetta Federico, Ansari Marc, Eddy Roosneck, Yves Chalandon.  
*T-Cell Depletion Improves the Composite End Point Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation.*

**2016**

53. N.Rock, M.Ansari, S.Ferrari-Lacraz, J. Villard, S. Waldvogel, V. McLin .  
*Risk factors for auto-immune hemolytic anemia after pediatric liver transplantation.*  
ESPGHAN, 2016
54. Valérie Arsenault, MD, The Thanh Diem Nguyen, MD Msc, Michel Duval, MD, Sophie Laberge, MD, Maja Krajinovic, MD, Marc Ansari, MD, Henrique Bittencourt, MD PhD  
*Impact of Busulfan systemic exposure prior to hematopoietic stem cell transplantation on pulmonary function tests in children.*  
CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada, CBMTG à Vancouver en avril 2016.
55. I.H. Bartelink, A. Lalmohamed , E.M.L. van Reij, C.C. Dvorak, R.M. Savic, J. Zwaveling, R.G.M. Bredius, A.C.G. Egberts, M. Bierings, M. Kletzel, P.J. Shaw, C.E. Nath, G. Hempel, M. Ansari, M. Krajinovic, Y. Theoret, M. Duval, R. Keizer, H. Bittencourt, M. Hassan, T. Gungor, R.F. Wynn, P. Veys, G.D.E. Cuvelier, S. Markt, R. Chiesa, M.J. Cowan , M.A. Slatter, M. K. Stricherz, C. Jennissen , J.R. Long-Boyle, J.J. Boelens.  
*Busulfan exposure predicts event free survival and toxicity after hematopoietic stem cell transplantation in children and young adult : a Multicenter Retrospective Cohort Analysis.*  
ASCPT 2016
56. Fabiën Belle , Laura Wengenroth, Annette Weiss, Grit Sommer, Maja Beck Popovic, Marc Ansari, Murielle Bochud, Claudia Kuehni for the Swiss Paediatric Oncology Group (SPOG).  
*Low adherence to dietary recommendations in adult childhood cancer survivors.*  
17 september 2016 ESPEN in Copenhagen.
57. Federico Simonetta, Stavroula Masouridi-Levrat, Yan Beauverd, Olga Tsopra, Yordanka Tirefort, Carolin Stephan, Karolina Polchlopek, Riccardo Faval, Carole Dantin, Marc Ansari, Eddy Roosnek, Yves Chalando.  
*T-cell depletion improves the composite end point graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.*  
EBMT 2016, Valence
58. Fabiën Belle (MSc) , Laura Wengenroth (PhD)<sup>a</sup>, Annette Weiss (MSc)<sup>a</sup>, Grit Sommer (PhD), Maja Beck Popovic (MD), Marc Ansari (MD), Murielle Bochud (MD, Prof), Claudia Kuehni (MD, Prof).  
*Awareness of National Dietary Recommendations in Adult Childhood Cancer Survivors Could Improve Healthcare Management.*  
Sixth edition of the Geneva Health Forum april 2016
59. V Pfeiffer, SM Redmond, M Schindler, Swiss Paediatric Oncology Group SPOG\*, G Michel, CE Kuehni  
*40 Years of collaboration between the swiss childhood cancer registry (scr) and swiss paediatric oncology group (spog) .*  
ENCR meeting 2016
60. Imke H. Bartelink , Arief Lalmohamed , Elisabeth M.L van Reij , Chris C. Dvorak , Rada M. Savic<sup>5</sup>, Juliette Zwaveling , Robbert G.M. Bredius , Antoine C.G. Egberts , Marc Bierings, Morris Kletzel , Peter J. Shaw , Christa E. Nath , George Hempel , Marc Ansari , Maya Krajinovic , Yves Theoret , Michel Duval , Ron J. Keizer , Henriette Bittencourt , Moustapha Hassan , Tayfun Güngör , Robert F. Wynn , Paul Veys , Geoff D.E. Cuvelier, Sarah Markt, Robert Chiesa , Morton J. Cowan , Mary A. Slatter , Missy K. Stricherz , Cathryn Jennissen, Janel R. Long-Boyle , Jaap Jan Boelens.  
*Busulfan Exposure Predicts Event Free Survival and Toxicity after Hematopoietic Cell Transplantation in Children and Young*

61. Jean-Hugues Dalle, Giovanna Lucchini, Adriana Balduzzi, Marianne Ifversen, Kirsi Jahnukainen, Kirsten Tryde Macklon, Astrid Ahler, Andrea Jarisch, Marc Ansari, Eric Beohou, Dorine Bresters, Selim Corbacioglu, Arnaud Dalissier, Cristina Diaz de Heredia Rubio, Tamara Diesch, Brenda Gibson, Thomas Klingebiel, Arjan Lankester, Anita Lawitschka, Rebecca Moffat, Christina Peters, Catherine Poirot, Nicole Saenger, Petr Sedlacek, Eugenia Trigos, Kim Vettenranta, Jacek Wachowiak, Andre Willasch, Michael von Wolff, Isaac Yaniv, Akif Yesilipek and <sup>8</sup>Peter Bader on behalf of the EBMT Paediatric Diseases Working Party.  
*State of the Art in Fertility Preservation in Children and Adolescents Undergoing Haematopoietic Stem Cell Transplantation.* Report on the Expert Meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29-30 September 2015
62. Ansari M, Patricia Curtis, Rao Uppugunduri, Bittencourt H, Krajinovic M.  
*GST haplotype influencing Busulfan clearance and dosing in conditioning before HSCT.* Rhodes, EBMT PWD may 2016
63. P Huez-Diaz Curtis, R C Uppugunduri, A K Tyagi, M Duval, H Bittencourt , M Krajinovic, M Ansari · *A Search for pharmacogenetic markers for predicting aGvHD in pediatric patients receiving Busulfan/ Cyclophosphamide conditioning regimen before HSCT.* Biology Perspective, ESPT Santorini meeting October 2016
64. Ansari M, Patricia Curtis, Rao Uppugunduri, Bittencourt H, Krajinovic M.  
*Pharmacogenomic of Busulfan in conditioning before HSCT.*  
Biology Perspective, ESPT Santorini meeting, DMT October 2016
65. Marc Ansari.  
*Personalised therapy for children: Hematopoietic Stem Cell Transplantation.*  
EBMT pediatric Working disease, Rhodes may 2016
66. Tiago Nava, Marc Ansari, Henrique Bittencourt, Maja Krajinovic. *GSTA1 genetic variants: a missing key factor in Busulfan first dose prediction models in conditioning before hematopoietic stem cell transplant in children<sup>2</sup>.* Biology Perspective, DMT ESPT Santorini meeting October 2016
67. André O. von Bueren, David T Jones, Tobias Goschzik, Rolf D. Kortmann, Katja von Hoff, Carsten Friedrich, Martin Mynarek, Anja zur Mühlen, Nicolas U. Gerber, Monika Warmuth-Metz, Frank Deinlein, Martin Benesch, Robert Kwiecien, Andreas Faldum, Volker Hovestadt, Paul A. Northcott, Joachim Kuehl, Stefan Pfister, Torsten Pietsch, Stefan Rutkowski.  
*Prognostic relevance of epigenetic/biological subgroups and MYCC / MYCN gene amplification in a homogenously treated metastatic medulloblastoma HIT2000 cohort aged 4-21 years.*  
17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016
68. Carsten Friedrich, Tarek Shalaby, Christoph Oehler, Martin Pruschy, Burkhardt Seifert, Monika Warmuth-Metz, Rolf-Dieter Kortmann, Stefan Rutkowski, Michael A. Grotzer, and André O. von Bueren.  
*Expression of tropomyosin receptor kinase C (TrkC) has no major impact on the response to therapy of medulloblastoma in vitro and in a clinical patient cohort.*  
17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016.
69. G.O. Janssens, L. Gandola , S. Bolle, H. Mandeville, M. Ramos-Albiac, K. van Beek, H. Benghiat, B. Hoeben , A. Morales La Madrid (Barcelona), E. Pecori , M. Peters, RD Kortmann, D. Hargrave, A.O. von Bueren, M. Massimino, D.G. van Vuurden, C.M. Kramm.  
*Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: analysis of the*

*SIOP-E-DIPG/HGG working group.*

17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016

70. Ole Juhnke, Martin Mynarek, André O. von Bueren, Carsten Friedrich, Nicolas U. Gerber, Rolf D. Kortmann, Torsten Pietsch, Monika Warmuth-Metz, Katja von Hoff, Stefan Rutkowski.  
*Effectivity of two different radiation-avoiding treatment regimens for young children with pineoblastoma - Results of the HIT2000 trial.*  
17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016
71. Carsten Friedrich, Alexander Kuhn, Martin Zimmermann, Marion Hoffmann, Ingrid Kuhnle, Johannes Nowak, Monika Warmuth-Metz, Torsten Pietsch, Martin Schrappe, Gabriele Escherich, Birgit Burkhardt, Rolf-Dieter Kortmann, André O. von Bueren, and Christof M. Kramm.  
*High-grade glioma arising in survivors of pediatric acute lymphoblastic malignancies: a cooperative analysis of the German HIT-HGG/-GBM and ALL-BFM/COALL studies.*  
17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016
72. Lindsey M. Hoffman, Sophie E.M. Veldhuijzen van Zanten, Niclas Colditz, Joshua Baugh, Brooklyn Chaney, Adam Lane, Christine Fuller, Lili Miles, Cynthia Hawkins, Ute Bartels, Eric Bouffet, Stewart Goldman, Sarah Leary, Nicholas K. Foreman, Roger Packer, Kathy Warren, Alberto Broniscer, Mark Kieran, Jane Minturn, Melanie Comito, Emmett Broxon, Chie-Schin Shih, Murali Chintagumpala, Soumen Khatua, Anne Sophie Carret, Tim Hassal, Nick Gottardo, David Ziegler, Brianna Lerme, Jenavieve Kirkendall, Renee Doughman, Marion Hoffmann, Matt Wollman, Rachel O'Keefe, Martin Benesch, Nicolas Gerber, Simon Bailey, Guirish Solanki, Veronica Biassoni, Maura Massimino, Veronica Biassoni, Filip Jadrijevic Cvrlje, Esther Hulleman, Rachid Drissi, Andre Oscar von Bueren, Torsten Pietsch, Gerrit Gielen, Dominik Sturm, David T. Jones, Stefan Pfister, Chris Jones, Darren Hargrave, Esther Sanchez, Brigitte Bison, Monika Warmuth-Metz, James Leach, Blaise Jones, Dannis G. van Vuurden, Christof M. Kramm, Maryam Fouladi.  
*Clinical, radiological, and histo-genetic characteristics of long-term survivors of diffuse intrinsic pontine glioma: a collaborative report from the International and SIOPe DIPG Registries.*  
17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016
73. Alan Mackay, Anna Burford, Janat Fazal Salom, Lynn Bjerke, Diana Carvalho, Mara Vinci, Valeria Molinari, Kathryn Taylor, Meera Nandhabalan, Sergey Popov, Kun Mu, Saoussen Trabelsi, Dorra Hmida-Ben Brahim, Rui M Reis, Andrew S Moore, Ho-Keung Ng, Andre O von Bueren, Michael Baudis, Chris Jones.  
*Integrated molecular meta-analysis of 1000 paediatric high grade glioma and DIPG.*  
17th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 12 - 15, 2016, Liverpool, United Kingdom Neuro-oncology, Volume 18 suppl 3 June 2016

## **2017**

74. Marc Ansari, P Huezio-Diaz Curtis, CRS Uppugunduri, MA Rezgui, T Nava, V Mlakar, L Lesne, Y Théoret, Y Chalandon, LL Dupuis, T Schechter, IH Bartelink, JJ Boelens, R Bredius, JH Dalle, S Azarnoush, P Sedlacek, V Lewis, M Champagne, C Peters, H Bittencourt and M Krajinovic.  
*GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation a Multicenter Study*  
On Behalf of The Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation. ASH San Diego 2016.
75. Imke H. Bartelink, Arief Lalmohamed, Elisabeth M.L van Reij, Chris C. Dvorak, Rada M. Savic, Juliette Zwaveling, Robbert G.M. Bredius, Antoine C.G. Egberts, Marc Bierings, Morris Kletzel, Peter J. Shaw, Christa E. Nath,

George Hempel, Marc Ansari, Maya Krajinovic, Yves Theoret, Michel Duval, Ron J. Keizer, Henriette Bittencourt, Moustapha Hassan, Tayfun Güngör, Robert F. Wynn, Paul Veys, Geoff D.E. Cuvelier, Sarah Marktel, Robert Chiesa, Morton J. Cowan, Mary A. Slatter, Missy K. Stricherz, Cathryn Jennissen, Janel R. Long-Boyle, Jaap Jan Boelens.

*Busulfan Exposure Predicts Event Free Survival and Toxicity after Hematopoietic Cell Transplantation in Children and Young Adults : a Multicenter Retrospective Cohort Analysis.*

EBMT, Valencia 2016

76. Delphine Arni, Valérie McLin, Barbara Wildhaber, Peter C. Rimensberger, Marc Ansari, Pierre Fontana, Oliver Karam.

*Effects of plasma transfusions on antithrombin levels after pediatric liver transplantation.*

9th IPTA, 27 may 2017, Spain

77. Rahel Kasteler, Linda Kam Mmed, Annette Weiss, Grit Sommer, Marc Ansari, Johannes Rischewski, Claudia E. Kuehni.

*Monitoring of pulmonary health in Swiss childhood cancer survivors: are guidelines necessary?*

GCB annual symposium of the graduate school for Health sciences in Bern and European Respiratory Society Conference 2017, Milano, Italy

78. Nicolas Waespe, Marc Ansari, Jean-Pierre Bourquin, Raffaele Renella, Nicolas von der Weid, Claudia E. Kuehni.

*Development of a nationwide germline dna biobank for childhood cancer survivors in switzerland .*

15<sup>th</sup> International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer, June 15-17, 2017, Atlanta, GA, USA

79. Yves Chalandon, Federico Simonetta, Carole Dantin, Aikaterini Koutsis, Anne-Claire Mamez, Yan Beauverd, Olga Tsopra, Audrey Simon, Stijn Bex, Caroline Stephan, Juan Felipe Rodriguez Morales, Karolina Polchlopek, Marc Ansari, Yordanka Tirefort, Eddy Roosnek, Stavroula Masouridi-Levrat.

*Efficient Prophylaxis with Defibrotide for Sinusoidal Obstruction Syndrome (SOS) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).*

ASH San Diego 2016

80. Yves Chalandon, Federico Simonetta, Carole Dantin, Aikaterini Koutsis, Anne-Claire Mamez, Yan Beauverd, Olga Tsopra, Audrey Simon, Stijn Bex, Caroline Stephan, Juan Felipe Rodriguez Morales, Karolina Polchlopek-Blasiak, Marc Ansari, Yordanka Tirefort, Eddy Roosnek and Stavroula Masouridi-Levrat.

*Defibrotide shows efficacy in the prevention of sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic stem cell transplantation: a retrospective study on 237 patients.*

The 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2017) March 26–29 2017 in Marseille, France.

81. Rao uppunguduri, Patricia Curtis, Henrique Bittencourt, Maja Krajinovic, Marc Ansari

*MGMT promoter gene's variant is associated with aGvHD in pediatric patients receiving busulfan and cyclophosphamide based myeloablative conditioning regimen prior to allogeneic hematopoietic stem cell transplantation.*

Biology Perspective octobre (2016)

82. F Baleyrier, M Schäppi-Tempia, E Ranza, A-L Rougemont, L Merlini, M Hofer, K Posfay-Barbe, M Ansari and G Blanchard-Rohner.

*A non-malignant tumoral presentation of a rare primary-immunodeficiency.*

ESID 2017, Edinburgh, Uk

#### 4. ABSTRACTS PRESENTED TO NATIONAL MEETINGS

##### 2011

1. Cimasoni L, Ansari M, Grazioli S, Gumy Pause F, Berner M, Ozsahin H.  
*Bronze baby syndrome in severe hemolytic disease of the newborn*  
Société suisse de pédiatrie, Assemblée annuelle. Montreux, September 2011  
Swiss Med Wkly, vol. 141 (2011), Suppl. No 187, p. 39S
2. Mattiello V, L'Huillier A, Cimasoni L, Gumy Pause F, Darani A, Ansari M, Ozsahin H.  
*Intrapleural vincristine infusion in a 7 year-old girl with an acute lymphoblastic leukemia : a case-report and review of the literature*  
Société suisse de pédiatrie, Assemblée annuelle. Montreux, September 2011  
Swiss Med Wkly, vol. 141 (2011), Suppl. No 187, p. 52S
3. Tissot C, Ansari M, Beghetti M, Aggoun Y, Finci F, Blouin JL, Fokstuen S.  
*Cardiac troponin 1 mutation responsible for idiopathic restrictive cardiomyopathy in a 4 year-old child*  
Société suisse de pédiatrie, Assemblée annuelle. Montreux, September 2011  
Swiss Med Wkly, vol. 141 (2011), Suppl. No 187, p. 49S
4. Yaron M, Beck-Popovic M, Girardin C, Phan-Hug F, Wunder D, Primi MP, Feki A, Ibecheole V, Simon JP, Schwitzgebel Turello R, Bellavia M, Ambrosetti A, Gumy-Pause F.  
*Fertility preservation in female pediatric cancer patients: a multidisciplinary approach*  
Société suisse de pédiatrie + Société suisse de chirurgie pédiatrique, Assemblée annuelle commune. Montreux, September 2011. Swiss Med Wkly, vol. 141 (2011), Suppl. No 187, p. 41S
5. Reverdin A, Soccac PM, Mornand A, Gumy-Pause F, Pache JC, Rougemont AL, Barazzone Argiroffo C.  
*Endobronchial inflammatory myofibroblastic tumor as a rare cause of left lung atelectasis*  
Société suisse de pédiatrie + Société suisse de chirurgie pédiatrique, Assemblée annuelle commune. Montreux, September 2011

##### 2012

6. Vandertuin L, Lacroix L, Mapelli E, Ozsahin H, Ansari M, Gervais A.  
*Hyperleukocytosis and its role in the pediatric emergency department*  
Société suisse de pédiatrie, Assemblée annuelle. Lucerne, May 2012  
Swiss Med Wkly, vol. 142 (2012), Suppl. No 192, p. 34S
7. Mattiello V, Larigaldie S, Zarra S, De Coulon G, Gumy Pause F, Ansari M, Ozsahin H.  
*Recombinant human erythropoietin in surgical correction of pediatric spinal deformities : a two years experience*  
Société suisse de pédiatrie, Assemblée annuelle. Lucerne, May 2012  
Swiss Med Wkly, vol. 142 (2012), vol. 142 (2012), Suppl. No 192, p. 31S

##### 2013

8. Girardin C, Schwitzgebel V, Phan-Hug F, Yaron M, Vidal I, Beck-Popovic M, Pernet S, Joseph JM, Wunder D, Primi MP, Bellavia M, Ambrosetti, A, Gumy-Pause F.  
*Fertility preservation in pediatric cancer patients : the multidisciplinary experience in Geneva and Lausanne*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 9S
9. Kanavaki I, McLin V, Belli D, Beck-Popovic M, Gumy-Pause F, Ansari M, Wildhaber B.  
*Liver transplantation as a treatment option in a child with hepatic embryonal sarcoma*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013

Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 32S

10. L'Huillier AG, Filaine P, Bernard F, Mattiello V, Crosazzo L, Delco C, Bissat E, Diana A, Gumy-Pause F, Ansari M.  
*Fever without focus? Keep hemophagocytic lymphohistiocytosis in mind*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 44S
11. Filaine P, L'Huillier AG, Mattiello V, Crosazzo Francini L, Bernard F, Ansari M, Gumy-Pause F.  
*Neurofibromatosis 1 (NF1) increases incidence of different types of paediatric cancers*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 44S
12. Crosazzo Francini L, Mattiello V, Filaine P, Bernard F, Ansari M, De Coulon G, Dhouib Chargui A, Rougement-Pidoux AL, Gumy-Pause F.  
*Langherans cell histiocytosis : an unusual cause of torticollis in children.*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 45S
13. Bernard F, Gumy-Pause F, Mattiello V, Filaine P, Crosazzo L, Roosnek E, Passweg J, Chalandon Y, Ansari M.  
*Administration of rituximab after hematopoietic stem cell transplantation can induce severe and prolonged hypogammaglobulinemia in children*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 46S
14. Gebistorf F, Crosazzo Francini L, Filaine P, Bernard F, Mattiello V, Martin G, Boehlen F, Gumy-Pause F, Ansari M.  
*Unusual cause of acute bruising in a previously healthy girl*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 46S
15. Pittet L, Emonet S, Ansari M, Girardin E, Schrenzel J, Siegrist CA, Posfay Barbe K.  
*Bordetella holmesii bacteremia in a child with nephroblastoma*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 50S
16. Rock N, Judas C, Mattiello V, Gumy-Pause F, Ozsahin H, Ansari M.  
*Arsenic trioxide: first line treatment of relapse of acute promyelocytic leukemia of children?*  
Société suisse de pédiatrie, Assemblée annuelle. Geneva, June 2013  
Swiss Med Wkly, vol. 143 (2013), Suppl. No 197, p. 48S

## 2014

17. D. Arni, F. Gumy-Pause, M. Ansari, J.A. Kremer Hovinga, V.A. McLin.  
*A rare combination of severe ADAMTS13 deficiency with acute liver failure*  
Société suisse de pédiatrie, Assemblée annuelle. Basel, June 2014  
Swiss Med Wkly, vol. 144 (2014), Suppl. No 203, p. 46S
18. Schindler M, Mitter V, Ansari M, Von der Weid N, Kuehni C.  
*Time-trends and predictors of childhood cancer survival in Switzerland*  
Swiss Public Health Conference 2014, 21. August 2014

## 2015

19. Dr Pauline Filaine, Dr Marc Ansari.  
*La gestion des symptômes chez un enfant en phase terminale d'un cancer.*  
Congrès de soins palliatifs CHUV septembre 2015
20. L Mader (MSc), CS Rueegg (PhD), J Vetsch (MSc), J Rischewski (MD), M Ansari (MD) CE Kuehni (PhD), G Michel (PhD).  
*Employment and income of parents of long-term childhood cancer survivors compared to the general population.*  
The Swiss Public Health Conference 2015.
21. Matthias Schindler, MSc , Ben D. Spycher, PhD , Roland A. Ammann, MD , Marc Ansari, MD , Gisela Michel, PhD Claudia E. Kuehni, MD, MSc.  
*Cause-specific late-mortality in 5-year survivors of childhood cancer in Switzerland.*  
The Swiss Public Health Conference 2015.
22. Marc Ansari.  
*La transplantation hématopoïétique allogénique de cellules souches et la drépanocytose.*  
La Drépanocytose ici et là-bas. 5 novembre 2015 CHUV, Lausanne

## 2016

23. Delphine Arni, Valérie McLin, Barbara Wildhaber, Peter C. Rimensberger, Marc Ansari, Pierre Fontana, Oliver Karam.  
*Effects of plasma transfusions on antithrombin levels after pediatric liver transplantation.*  
Der Schweizerischen Gesellschaft für Kinderchirurgie am 8./9. September 2016 in St.Gallen, Suisse
24. Marc Ansari.  
*Personalised therapy for children: Hematopoietic Stem Cell Transplantation.*  
SSCPT, Société Suisse de médecine Interne, mai bale 2016

## 2017

25. Patricia Huezo-Diaz, Chakradhara Rao Uppugunduri, Jayaraman Muthukumar, Mohamed Rezgui, Christina Peters, Peter Bader, Michel Duval, Henrique Bittencourt, Maja Krajinovic, Marc Ansari.  
*Association of CTH Variant with Sinusoidal Obstruction Syndrome in Children Receiving Intravenous Busulfan and Cyclophosphamide before Hematopoietic Stem Cell Transplantation.*  
SSMI/SSCPT, mai Lausanne 2017
26. F Baleyrier, M Schächli-Tempia, E Ranza, A-L Rougemont, L Merlini, M. Hofer, K. Posfay-Barbe, M n Ansari and G Blanchard-Rohner.  
*A non-malignant tumoral presentation of a rare primary-immunodeficiency.*  
Swiss Pediatric meeting, juin 2017 (St Galle).Suisse
27. Lennart Opitz, Benjamin Volkmer, Andrea Mauracher, Marc Ansari, Daniela Kaiser, Ulrich Heining, Bernd Bodenmiller, Lucas Pelkmans, Ralph Schlapbach, Stefano Vavassori, Jana Pachlopnik Schmid.  
*A High-Performance Analysis Pipeline to find Disease-Causing Mutations in Patients with Primary Immunodeficiencies.*  
Swiss Pediatric meeting, juin 2017 (St Galle), Suisse



## 5. ABSTRACTS UNPUBLISHED

### 2011

1. Ansari M.  
*Update on the EBMP busulfan study*  
Groupe d'oncologie pédiatrique suisse, Annual Meeting, Lugano, January 2011
2. Ansari M, Ozsahin AH, Krajcinovic M.  
*The busulfan SPOG study*  
Groupe d'oncologie pédiatrique suisse, Annual Meeting, Lugano, January 2011
3. Ansari M, Roosneck E.  
*Impact of NK cells post-hematopoietic stem cell transplantation*  
4ème Journée de la recherche clinique. Geneva, May 2011
4. Rezgui MA, Ansari M, Thérot Y, Duval M, Vachon MF, Bittencourt H, Krajcinovic M.  
*Genetic determinants of the busulfan pharmacokinetics*  
12th International congress of human genetics. Montréal, October 2011
5. Gollut S, Stuckelberger S, Ansari M.  
*Le suivi des familles après le décès d'un enfant en soins palliatifs : un besoin ?*  
Journée nationale des soins palliatifs. Lausanne, November 2011
6. Gumy-Pause F, Ozsahin H, Turello R, Girardin C, Phan-Hug F, Wunder D, Primi MP, Simon JP, Schwitzgebel V, Beck-Popovic M, Bellavia M, Ambrosetti A, Yaron M.  
*Female fertility preservation in paediatric cancer patients: a multidisciplinary approach.*  
Bulletin suisse du cancer, vol. 31 (2011), pp. 321-324

### 2012

7. Ansari M, Strunk D, Schallmoser K, Delco C, Rougemont AL, Moll S, Villard J, Gumy Pause F, Chalandon Y, Parvex P, Passweg J, Ozsahin H, Kindler V.  
*Impact of mesenchymal stem cell transfusion on thrombotic microangiopathy post-hematopoietic stem cell transplantation*  
5ème Journée de la recherche clinique. Geneva, May 2012
8. Versace F, Uppungunduri C, Krajcinovic M, Théoret Y, Gumy Pause F, Ozsahin H, Mangin P, Staub C, Ansari M.  
*Quantification of sulfolane, a metabolite of busulfan, in plasma by gas chromatography and tandem mass spectrometry : a new method for evaluating the role of sulfolane and metabolic fate of busulfan*  
5ème Journée de recherche clinique. Geneva, May 2012
9. Gumy Pause F, Pardo B, Koshbeen-Boudal M, Ansari M, Gayet-Ageron A, Sappino AP, Attiyeh EF, Ozsahin H.  
*GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma*  
5ème Journée de la recherche clinique. Geneva, May 2012
10. Gollut S, Stuckelberger S, Ansari M.  
*Le suivi des familles en onco-hématologie pédiatrique après le décès d'un enfant : un besoin ?*  
5ème Congrès international de soins palliatifs pédiatriques. Montréal, October 2012
11. Mandriota S, Buser R, Lesne L, Ozsahin H, Ansari M, Gumy Pause F  
*Function to neuroblastoma progression*  
Advances in neuroblastoma research association, Annual meeting. Toronto, juin 2012

## 2013

12. Ansari M.  
*La pharmacogénomique et pharmacocinétique chez l'enfant en transplantatin de cellules souches hématopoïétique.*  
Congrès scientifique de la société suisse d'oncologie pédiatrique, Lugano, February 2013
12. Uppugunduri C, Ansari M.  
*A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry*  
Congrès scientifique de la société suisse d'oncologie pédiatrique, Lugano, February 2013
13. Mandriota S, Gumy-Pause F, Ansari, M.  
*Ataxia-telangiectasia-mutated (ATM) signalling in neuroblastoma*  
Congrès scientifique de la société suisse d'oncologie pédiatrique, Lugano, February 2013
14. Ansari M.  
*Pharmacogenomic in ALL SCT children*  
Interantional BFM Kiel, April 2013
15. Huezo-Diaz P, Uppugunduri CR, Tyagi A, Rezgui M, Bernard F, Chalandon Y, Duval M, Bittencourt H, Krajinovic M.  
*Metabolic enzyme gene variants predispose children receiving a busulfan/ cyclophosphamide-based myeloablative conditioning to veno-occlusive disease*  
European group for bone and marrow transplantation, 39th Annual meeting. Londres, avril 2013  
Bone Marrow Transplant, vol. 48 (2013), Suppl. No 2, No 752

## 2014

16. Uppugunduri CR, Daali Y, Rezgui MA, Huezo-Diaz P, Tyagi AK, Rousseau J, Duval M, Bittencourt H, Krajinovic M, Ansari M.  
*Association of Busulfan metabolic ratios (Busulfan/ Sulfolane) with clinical outcomes of allogenic hematopoietic stem cell transplantation in children receiving Busulfan based myeloablative conditioning*  
Swiss pediatric oncology group, Annual meeting. Lugano, January 2014
17. Mandriota S, Ansari M, Gumy Pause F.  
*Role of ataxia-telangiectasia mutated (ATM) inactivation in neuroblastoma progression*  
Société suisse d'oncologie pédiatrique, Congrès scientifique. Lugano, January 2014
18. Ansari M.  
*The add on study of FORUM SCT PED study*  
International BFM Prague, April 2014
19. Ansari M, Rezgui MA, Théoret Y, Uppugunduri CR, Duval M, Peters C, Bittencourt H, Krajinovic M.  
*Association of glutathione S-transferase gene variations, busulfan exposure and clinical outcomes in children receiving intravenous busulfan before hematopoietic stem cell transplantation*  
Journée de recherche clinique. Geneva HUG, May 2014
20. Acosta-Martin AE, Antinori-Malaspina P, Uppugunduri CR, Daali Y, Ansari M Hochstrasser DF, Scherl A, Lescuyer P, Müller M.  
*Development of a workflow for the detection of drug-derived adducts on proteins*  
Human proteome organization, 13th World congress. Madrid, October 2014

## 2016

21. Eva Choong , Chakradhara Rao Uppugunduri Satyanarayana, Denis Marino, Melanie Kuntzinger , Fabienne Doffey Lazeyras, Rodolfo Lo Piccolo, Yves Chalandon, Christina Peters, Youssef Daali , Marc Ansari

*Busulfan therapeutic drug monitoring for children at Geneva University Hospital*

Journée recherche clinique, HUG mai 2016

22. Marc Ansari, Patricia Huezo-Diaz, Aziz Mohamed Rezgui, Sarah Marktel, Michel Duval, Henrique Bittencourt, Barbara Cappelli, Maja Krajinovic.  
*Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients*  
Journée recherche clinique, HUG mai 2016
23. Stefano J. Mandriota<sup>1</sup>, Linda J. Valentijn, Laurence Lesne<sup>1</sup>, David R. Betts<sup>3</sup>, Denis Marino<sup>1</sup>, Mary Boudal Khoshbeen<sup>1</sup>, Wendy B. London<sup>4</sup>, Anne-Laure Rougemont, Edward F. Attiyeh, John M. Maris, Michael D. Hogarty, Jan Koster, Jan J. Molenaar, Rogier Versteeg, Marc Ansari<sup>1</sup>, Fabienne Gumy-Pause  
*Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism*  
Journée recherche clinique, HUG mai 2016
24. Chakradhara Rao S Uppugunduri, Marc Ansari.  
*Long-term evaluation of Busulfan methods for therapeutic drug monitoring in pediatric patients*  
Geneva. Société Suisse d'oncology pédiatrique, Bern 3 juin 2016
25. Marc Ansari.  
*GSTA1 haplotypes affect busulfan clearance and toxicity in paediatric patients undergoing hematopoietic stem cell transplantation – Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Group.*  
Société Suisse d'oncology pédiatrique, Bern 3 juin 2016
26. Fabienne Gumy-Pause, Marc Ansari.  
*Male fertility preservation using testicular tissue cryopreservation before highly gonadotoxic cancer treatment - a multi-centric study.*  
Société Suisse d'oncology pédiatrique, Bern 3 juin 2016.
27. Patricia Curtis, Marc Ansari.  
*MGMT associated with acute GVHD in pediatric patients who underwent haematopoietic stem cell transplantation.*  
Société Suisse d'oncology pédiatrique, Bern 3 juin 2016.
28. Chakradhara Rao S Uppugunduri, Marc Ansari.  
*Clinical validation of dried blood sampling method for therapeutic drug concentration monitoring of busulfan in pediatric patients - preliminary results.*  
Société Suisse d'oncology pédiatrique, Bern 3 juin 2016.
29. Marion Hoffmann, André von Bueren, Christof Kramm  
*Studienupdate: HIT-HGG: HIT-HGG-2007, HIT-HGG-2013 sowie HIT-HGG-Rez-Immunovac. Tagung des Behandlungsnetzwerks HIT für Kinder und Jugendliche mit Hirntumoren*  
15.-16. April 2016 in Göttingen
30. von Bueren AO.  
*Multimodale Behandlungskonzepte bei malignen Hirntumoren im Kindes- und Jugendalter unter besonderer Berücksichtigung der malignen Gliome*  
Wissenschaftliches Symposium, Zukunftsperspektiven der Pädiatrischen Radioonkologie. University of Marburg. 04/2016.

31. Patricia Huezo-Diaz, Chakradhara Rao Uppugunduri, Jayaraman Muthukumar, Mohamed Rezgui, Christina Peters, Peter Bader, Michel Duval, Henrique Bittencourt, Maja Krajinovic, Marc Ansari.  
*Association of CTH Variant with Sinusoidal Obstruction Syndrome in Children Receiving Intravenous Busulfan and Cyclophosphamide before Hematopoietic Stem Cell Transplantation.*  
SSMI/SSCPT, mai Lausanne 2017
32. Ansari, Marc.  
*Busulfan individualised therapy.* IBFM  
Jerusalem, Israel 2017
33. Ansari, M, Bittencourt H, Krajinovic M. Bugnes  
*A new prospective trial.*  
IBFM Jerusalem, Israel 2017
34. von Bueren AO, Kortmann RD, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S. *Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters.* 10ème Journée de la recherche clinique - jeudi 11 mai 2017, University of Geneve
35. Von Büren André. *SIOP DIPG Registry and / or can we open a SIOPE-Infant HGG registry.* SPOG meeting, lugano, 27 january 2017
36. Gumy-Pause Fabienne. *Male fertility preservation using testicular tissue cryopreservation before highly gonadotoxic cancer treatment – a multicentric study,* Geneva

**Total: 108 articles,** 82 abstracts congrès internationaux, 27 abstarcts nationaux, 36 abstracts autres (soit **145 abstracts depuis 2011**).

Juin 2017


